Scancell HoldingsSCNLF 16 Return-on-Tangible-Asset is -65.82% as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 16/100. The stock has 2 warning signs investors should review. Among 1,412 Biotechnology companies, Scancell Holdings ranks better than 52.55% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Scancell Holdings's annualizedNet Income for the quarter that ended in Oct. 2025 was $-15.33 Mil. Scancell Holdings's average total tangible assets for the quarter that ended in Oct. 2025 was $23.29 Mil. Therefore, Scancell Holdings's annualized Return-on-Tangible-Asset for the quarter that ended in Oct. 2025 was -65.82%.
The historical rank and industry rank for Scancell Holdings's Return-on-Tangible-Asset or its related term are showing as below:
SCNLF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -87.89 Med: -55.52 Max: -11.32
Current: -32.86
During the past 13 years, Scancell Holdings's highest Return-on-Tangible-Asset was -11.32%. The lowest was -87.89%. And the median was -55.52%.
SCNLF's Return-on-Tangible-Asset is ranked better than 52.55% of 1412
companies
in the Biotechnology industry
Industry Median: -35.475
vs SCNLF: -32.86
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Scancell Holdings Return-on-Tangible-Asset Related Terms
Scancell Holdings Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Scancell Holdings's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCNLF vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Scancell Holdings's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scancell Holdings Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scancell Holdings's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Scancell Holdings's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Oct. 2025) net income data.
What does a Return-on-Tangible-Asset of -65.82% mean?
Scancell Holdings (SCNLF) has a Return-on-Tangible-Asset of -65.82% as of Oct. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Scancell Holdings and its competitors. According to the industry distribution chart, Scancell Holdings ranks #670 out of 1412 companies in the Biotechnology industry, placing it in the top 47.5%.
Is Scancell Holdings' Return-on-Tangible-Asset too high?
Scancell Holdings' current Return-on-Tangible-Asset is -65.82%. Based on the distribution chart, Scancell Holdings ranks #670 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Scancell Holdings has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Scancell Holdings ranks #670 out of 1412 companies for Return-on-Tangible-Asset. This puts Scancell Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Scancell Holdings and its competitors. Scancell Holdings's current Return-on-Tangible-Asset is -65.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Return-on-Tangible-Asset of -65.82%. The current Return-on-Tangible-Asset is -65.82%. Scancell Holdings' overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Return-on-Tangible-Asset is -65.82% as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
16GF Score
Get the complete analysis for SCNLF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCNLF has been successfully added to your 
